{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T13:00:50Z","timestamp":1762866050949},"reference-count":17,"publisher":"American Society for Microbiology","issue":"10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clin. Vaccine Immunol."],"published-print":{"date-parts":[[2012,10]]},"abstract":"<jats:title>ABSTRACT<\/jats:title><jats:p>We conducted a multicenter trial in Canada to assess the value of using trueness controls (TC) for rubella virus IgG and hepatitis B virus surface antibody (anti-HBs) serology to determine test performance across laboratories over time. TC were obtained from a single source with known international units. Seven laboratories using different test systems and kit lots included the TC in routine assay runs of the analytes. TC measurements of 1,095 rubella virus IgG and 1,195 anti-HBs runs were plotted on Levey-Jennings control charts for individual laboratories and analyzed using a multirule quality control (MQC) scheme as well as a single three-standard-deviation (3-SD) rule. All rubella virus IgG TC results were \u201cin control\u201d in only one of the seven laboratories. Among the rest, \u201cout-of-control\u201d results ranged from 5.6% to 10% with an outlier at 20.3% by MQC and from 1.1% to 5.6% with an outlier at 13.4% by the 3-SD rule. All anti-HBs TC results were \u201cin control\u201d in only two laboratories. Among the rest, \u201cout-of-control\u201d results ranged from 3.3% to 7.9% with an outlier at 19.8% by MQC and from 0% to 3.3% with an outlier at 10.5% by the 3-SD rule. In conclusion, through the continuous monitoring of assay performance using TC and quality control rules, our trial detected significant intra- and interlaboratory, test system, and kit lot variations for both analytes. In most cases the assay rejections could be attributable to the laboratories rather than to kit lots. This has implications for routine diagnostic screening and clinical practice guidelines and underscores the value of using an approach as described above for continuous quality improvement in result reporting and harmonization for these analytes.<\/jats:p>","DOI":"10.1128\/cvi.00294-12","type":"journal-article","created":{"date-parts":[[2012,8,16]],"date-time":"2012-08-16T01:11:48Z","timestamp":1345079508000},"page":"1624-1632","source":"Crossref","is-referenced-by-count":6,"title":["Results of Continuous Monitoring of the Performance of Rubella Virus IgG and Hepatitis B Virus Surface Antibody Assays Using Trueness Controls in a Multicenter Trial"],"prefix":"10.1128","volume":"19","author":[{"given":"Tamara","family":"Kruk","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sam","family":"Ratnam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jutta","family":"Preiksaitis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Allan","family":"Lau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Todd","family":"Hatchette","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Greg","family":"Horsman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul","family":"Van Caeseele","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brian","family":"Timmons","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Graham","family":"Tipples","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"235","published-online":{"date-parts":[[2012,8,15]]},"reference":[{"key":"key20180919073626_B1","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1093\/clinchem\/39.8.1638","article-title":"Comparison of quality-control rules used in clinical chemistry laboratories","volume":"39","author":"Bishop","year":"1993","journal-title":"Clin. Chem."},{"key":"key20180919073626_B2","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.vaccine.2011.11.045","article-title":"Seroprevalence of low rubella IgG antibody levels among antenatal women in England tested by NHS Blood and Transplant: 2004-2009. Is rubella susceptibility increasing?","volume":"30","author":"Byrne","year":"2012","journal-title":"Vaccine"},{"key":"key20180919073626_B3","first-page":"113","article-title":"Probability and the Westgard rules","volume":"33","author":"Carroll","year":"2003","journal-title":"Ann. Clin. Lab. Sci."},{"key":"key20180919073626_B4","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1128\/JCM.30.3.633-641.1992","article-title":"Multicenter evaluation of five commercial rubella virus immunoglobulin G kits which report in international units per milliliter","volume":"30","author":"Dimech","year":"1992","journal-title":"J. Clin. Microbiol."},{"key":"key20180919073626_B5","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1111\/j.1423-0410.2010.01314.x","article-title":"Calibration of the second international standard for hepatitis B immunoglobulin in an international collaborative study","volume":"99","author":"Ferguson","year":"2010","journal-title":"Vox Sang."},{"key":"key20180919073626_B6","doi-asserted-by":"crossref","first-page":"2899","DOI":"10.1016\/S0264-410X(02)00233-5","article-title":"Anti-HBs levels after hepatitis B immunisation depend on test reagents: routinely determined 10 and 100 IU\/L seroprotection levels unreliable","volume":"20","author":"Heijtink","year":"2002","journal-title":"Vaccine"},{"key":"key20180919073626_B7","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.coi.2010.12.013","article-title":"Hepatitis B virus infection, its sequelae, and prevention by vaccination","volume":"23","author":"Huang","year":"2011","journal-title":"Curr. Opin. Immunol."},{"key":"key20180919073626_B8","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1128\/JCM.02430-07","article-title":"Comparison of nine commercially available assays for quantification of antibody response to hepatitis B virus surface antigen","volume":"46","author":"Huzly","year":"2008","journal-title":"J. Clin. Microbiol."},{"key":"key20180919073626_B9","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.jcv.2011.01.009","article-title":"Performance of the DiaSorin LIAISON\u00ae anti-HBs II for the detection of hepatitis B surface antibodies: comparison with the Abbott Architect anti-HBs assay","volume":"50","author":"Kinn","year":"2011","journal-title":"J. Clin. Virol."},{"key":"key20180919073626_B10","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1093\/ajcp\/20.11_ts.1059","article-title":"The use of control charts in the clinical laboratory","volume":"20","author":"Levey","year":"1950","journal-title":"Am. J. Clin. Pathol."},{"key":"key20180919073626_B11","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1373\/clinchem.2011.164012","article-title":"Roadmap for harmonization of clinical laboratory measurement procedures","volume":"57","author":"Miller","year":"2011","journal-title":"Clin. Chem."},{"key":"key20180919073626_B12","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1080\/15321810701454953","article-title":"Comparison of two commercial immunoassays for the detection of anti-rubella IgM and IgG in pediatric patients","volume":"28","author":"Oliveira","year":"2007","journal-title":"J. Immunoassay Immunochem."},{"key":"key20180919073626_B13","volume-title":"Economic control of quality of manufactured product","author":"Shewhart","year":"1931"},{"key":"key20180919073626_B14","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1093\/ajcp\/106.2.170","article-title":"Rubella immunity. Defining the level of protective antibody","volume":"106","author":"Skendzel","year":"1996","journal-title":"Am. J. Clin. Pathol."},{"key":"key20180919073626_B15","first-page":"139","article-title":"Reference materials and commutability","volume":"28","author":"Vesper","year":"2007","journal-title":"Clin. Biochem. Rev."},{"key":"key20180919073626_B16","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1093\/clinchem\/27.3.493","article-title":"A multi-rule Shewhart chart for quality control in clinical chemistry","volume":"27","author":"Westgard","year":"1981","journal-title":"Clin. Chem."},{"key":"key20180919073626_B17","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.1093\/clinchem\/23.10.1857","article-title":"Performance characteristics of rules for internal quality control: probabilities for false rejection and error detection","volume":"23","author":"Westgard","year":"1977","journal-title":"Clin. Chem."}],"container-title":["Clinical and Vaccine Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1128\/CVI.00294-12","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,29]],"date-time":"2021-07-29T20:46:37Z","timestamp":1627591597000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/CVI.00294-12"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,8,15]]},"references-count":17,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2012,9,26]]},"published-print":{"date-parts":[[2012,10]]}},"alternative-id":["10.1128\/CVI.00294-12"],"URL":"https:\/\/doi.org\/10.1128\/cvi.00294-12","relation":{},"ISSN":["1556-6811","1556-679X"],"issn-type":[{"value":"1556-6811","type":"print"},{"value":"1556-679X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,8,15]]}}}